Opinion

Video

Emerging Therapies: a look at the current data: ALIGN

Key Takeaways

  • Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
  • Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
SHOW MORE

Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.

  1. In the phase 3 ALIGN trial (NCT04573478), atrasentan demonstrated a 36% relative reduction in proteinuria with placebo after 36 weeks of treatment. What other data points would be relevant for clinicians?
Related Videos
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.